ReviewJournal of medical case reports2025
Unraveling COVID-19-vaccination-induced bullous pemphigoid: a case report and review of the literature.
Review in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 vaccines have been instrumental in combating the global pandemic, yet their potential side effects, including autoimmune conditions such as bullous pemphigoid, remain an area of concern. This case highlights the development of bullous pemphigoid following coronavirus disease 2019 vaccination and includes a comprehensive review of similar cases reported in the literature, emphasizing its novelty and clinical significance. CASE PRESENTATION: An elderly British man in his 80s with type 2 diabetes mellitus developed blistering lesions 21 days after receiving his third dose of coronavirus disease 2019 vaccine (Moderna). Clinical examination revealed erythematous plaques and bullae on the trunk and limbs. Histopathological evaluation and immunofluorescence confirmed the diagnosis of bullous pemphigoid. Treatment included corticosteroids, doxycycline, and immunosuppressants. Despite initial improvement, a severe flare-up necessitated hospitalization and wound care management. A systematic review identified 50 reported cases of bullous pemphigoid linked to coronavirus disease 2019 vaccination, with the Pfizer-BioNTech vaccine implicated in most cases (64%), followed by Moderna (18%). Symptom onset typically occurred after the first dose in 52% of cases.
conclusionThis case underscores the need for vigilance regarding autoimmune phenomena such as bullous pemphigoid following coronavirus disease 2019 vaccination. Awareness of such potential adverse effects is crucial to ensure timely diagnosis and management, ultimately contributing to patient safety and guiding future vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.